Since several studies demonstrated the antiproliferative role of ER-β (202–205), castration-resistant prostate cancer cells were treated with the combination of Ro 48-8071 and ER-β agonist diarylpropionitrile showing enhanced activity in inhibiting cell viability. This evidence concerns the gene ESR2 and prostate carcinoma.